1 Groupe PiLeJe, 37 Quai de Grenelle, 75015 Paris Cedex 15, France.
2 Etap-Lab, 13 Rue du Bois de la Champelle, 54500 Vandœuvre-lès-Nancy, France.
Benef Microbes. 2018 Feb 27;9(2):299-309. doi: 10.3920/BM2017.0084. Epub 2018 Feb 7.
Oral probiotics potential for the management of dermatological diseases is vast. However, results of available studies in skin diseases, such as atopic dermatitis (AD), are inconsistent, partly because probiotic effects are strain specific. Careful selection of probiotic strains is therefore indispensable to ensure efficacy of treatment. In this study, Lactobacillus salivarius LA307, Lactobacillus rhamnosus LA305 and Bifidobacterium bifidum PI22, three strains that were previously identified for their interesting immunomodulatory properties in allergy and/or colitis models, were assessed in the prevention of chronic skin inflammation induced by repeated applications of 12-O-tetradecanoylphorbol-13-acetate in hairless SKH-1 mice. Macroscopic and microscopic evaluation of skin lesions was performed together with measurements of serum levels of interleukin (IL)-1β, IL-6, tumour necrosis factor alpha (TNF-α), IL-17, IL-22, IL-10 and IL-4. Daily oral treatment with the three strains at the dose of 1×10 cfu/day for 3 weeks limited the development of chronic skin inflammation, the effects being strain dependent. Indeed the two Lactobacillus strains significantly limited the intensity of skin inflammation both at the macroscopic and microscopic levels. Macroscopic observations were correlated to the histological observations and the resulting microscopic score. This limitation of the development of AD-like skin lesions involved the modulation of cytokine production. Treatment with the two Lactobacillus strains induced a decrease in the serum levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, IL-17, IL-22 and at the opposite an increase in the production of the anti-inflammatory cytokine IL-10 and also of IL-4. Globally, B. bifidum PI22 had lower benefits. These results obtained in mice suggest that L. salivarius LA307 and L. rhamnosus LA305 could be good candidates for preserving skin integrity and homeostasis via the modulation of the gut microbiota and that their use could be beneficial in dermatological conditions such as AD.
口腔益生菌在皮肤病管理方面具有广阔的应用前景。然而,目前关于益生菌在皮肤病(如特应性皮炎)中的应用的研究结果并不一致,部分原因是益生菌的作用具有菌株特异性。因此,仔细选择益生菌菌株对于确保治疗效果是不可或缺的。在这项研究中,我们评估了三种先前被鉴定为具有在过敏和/或结肠炎模型中具有有趣的免疫调节特性的菌株,即唾液乳杆菌 LA307、鼠李糖乳杆菌 LA305 和双歧杆菌 BI22,用于预防 12-O-十四烷酰佛波醇-13-乙酸酯(TPA)反复应用诱导的无毛 SKH-1 小鼠慢性皮肤炎症。对皮肤病变进行宏观和微观评估,同时测量血清中白细胞介素(IL)-1β、IL-6、肿瘤坏死因子-α(TNF-α)、IL-17、IL-22、IL-10 和 IL-4 的水平。三种菌株每天口服 1×10 cfu/天,连续 3 周,剂量依赖性地限制了慢性皮肤炎症的发展。实际上,两种乳杆菌菌株在宏观和微观水平上都显著地限制了皮肤炎症的强度。宏观观察与组织学观察相关,并且与微观评分相关。这种类似特应性皮炎皮肤病变的发展的限制涉及细胞因子产生的调节。两种乳杆菌菌株的治疗诱导了促炎细胞因子 IL-1β、IL-6、TNF-α、IL-17、IL-22 的血清水平降低,而抗炎细胞因子 IL-10 和 IL-4 的产生增加。总体而言,双歧杆菌 BI22 的益处较低。这些在小鼠中获得的结果表明,唾液乳杆菌 LA307 和鼠李糖乳杆菌 LA305 可以通过调节肠道微生物群来保护皮肤完整性和内稳态,并且它们在特应性皮炎等皮肤病中的应用可能是有益的。